University of Cologne
https://portal.uni-koeln.de/en/uoc-home
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From University of Cologne
Exelixis Fishes Artemis Out of the Ice of Germany's Biotech Winter
Exelixis Pharmaceuticals Inc.'s acquisition of its Artemis Pharmaceuticals GMBH affiliate makes strategic sense. But the bargain price paid sends a clear and frightening signal to investors in German start-ups: the real values of some of these companies--even some of those with the highest profiles--may be approaching fire-sale levels.
US Biotech Subsidiaries in Germany
It is tempting during these dark days of the US biotech industry to contemplate establishing a presence in Europe, particularly Germany. The principal lure is funding. A typical German funding package for a US biotech could include a matching grant of $3 million by a German federal agency, alongside a $3 million investment by a German VC fund, as well as another $3 million in state and regional money.
Germany's Biotech Boomlet
A teutonic wave of biotech start-ups is gathering, fed by government money, new venture funds and a handful of academics. But given the cultural and managerial obstacles, it's not certain that this wave will have the energy to reach the shore.
Company Information
- Industry
- Academic and Research Institutions
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice